Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
申请人:PFIZER INC.
公开号:EP0995751B1
公开(公告)日:2005-06-29
Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction
申请人:Pfizer Inc.
公开号:US06407114B1
公开(公告)日:2002-06-18
There is provided compounds of formula IA and of formula IB,
wherein R1, R2, R3, R4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.